On August 18, the press conference for the 2020 Top 100 Enterprises in Shanghai was held in which the 2020 Top 100 Enterprises in Shanghai and 2020 Top 100 Private Enterprises in Shanghai and other rankings were announced. With its worldwide comprehensive industrial strength and an operating revenue of RMB 142.98 billion, Fosun ranked second on the Top 100 Private Enterprises in Shanghai and 15^th on the Top 100 Enterprises in Shanghai. As a technology innovation-driven group, Fosun has been deeply engaged in the three business sectors of health, entertainment, and wealth management. Since the outbreak of COVID-19, Fosun has tapped into its expertise and tenacity to control the spread and has continued to provide high-quality products and services for global households.

The press conference was jointly sponsored by the Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, Shanghai Federation of Economic Organizations, and Jiefang Daily. The relevant rankings not only showcased company strength but also served as a barometer for Shanghai's economic transformation and high-quality development.

The data showed that the revenue threshold of top 100 private enterprises in Shanghai in 2020 increased from RMB 1.85 billion last year to RMB 2.31 billion. The private enterprises in Shanghai are still growing their business, and their scale of operation, economic and labor efficiency maintained rapid growth compared with a year earlier. The total operating revenue of top 100 private enterprises in Shanghai in 2019 amounted to RMB 1882.68 billion, which increased by RMB 308.71 billion with a growth rate of 19.61%. According to the statistics, 98 of the 100 enterprises provided their tax amount which totaled RMB 81.15 billion, which increased by RMB 10.09 billion or 14.2% year-over-year. Fosun International ranked second with a tax amount of RMB 7.35 billion.

Fosun, headquartered in Shanghai, is based in China but has a global expansion strategy. As of December 31, 2019, Fosun is operating with assets worth RMB 715.7 billion, ranking 371st in The Global 2000 released by Forbes in 2020.

Since the outbreak of COVID-19 this year, Fosun has mobilized global resources and actively participated in the global pandemic response. After the Chinese government implemented regular prevention and control measures, Fosun broke new ground and took new opportunities and continued to innovate to support economic recovery and stimulate the economy nationwide.

High-profile big health sector

BNT162b1, an mRNA vaccine product jointly developed by Fosun Pharma and BioNTech, has entered the clinical trial stage in China. In the meantime, Zercepac (trastuzumab) ®(HLX02), which was independently developed and produced by Henlius as a subsidiary of Fosun Pharma, has gained market approval from the European Union and the National Medical Products Administration (NMPA) of China as the first domestic monoclonal antibody biological analog drug in China and Europe.

The big consumption sector

Yuyuan Tourist Mart, a subsidiary of Fosun, has created and upgraded the "food playground" block with an immersive experience with the resurgence of traditional Chinese culture which has become a must-see attraction for Shanghai's night economy. The BFC Bund Fengjing market, a new pop-up shop pedestrian street in the Bund Financial Center, is 800 m east of Yuyuan and quite popular. It has attracted more than 1.5 million visitors over the past two months, effectively promoting the growth of sales revenue around the business circle.

Meanwhile, Fosun Tourism Group has achieved rapid business recovery

In July, the occupancy rate of its Atlantis Sanya hotel was over 90%. The Club Med gradually achieved business recovery starting in April. Its five open domestic resorts had an occupancy rate of more than 90%, and its 25 Club Med resorts worldwide resumed business at the end of July.

Smart manufacturing

The global headquarters of FFT Automation Technology Co., Ltd. (FFT), which is an international holding subsidiary of Fosun, also started plant construction in Shanghai in early August with a total investment of nearly RMB 5 billion. It will make an important contribution to the products "Made in Shanghai" and explore new opportunities for global development in the new era of "dual circulation".